Martine Rothblatt, the chief executive of United Therapeutics Corporation, has sold approximately $5.09 million (£3.94 million) worth of shares in the company, according to a regulatory filing with the US Securities and Exchange Commission. The transaction, conducted on 14 July 2026, involved the sale of 14,000 shares at prices ranging from $363.50 to $364.00 per share.
The sale represents a routine insider disposal, though it does not reduce Rothblatt's substantial remaining stake in the biotechnology firm she founded. United Therapeutics, headquartered in Silver Spring, Maryland, specialises in treatments for pulmonary arterial hypertension and other chronic lung conditions. The company's stock has seen volatility in recent months amid broader biotech sector fluctuations.
For UK investors with exposure to US equities via pension funds or exchange-traded funds, insider sales can serve as a signal of management sentiment, though they are often pre-planned under trading plans. The FTSE 100 closed at 8,212.45 on Wednesday, down 0.3 per cent, as global markets reacted to mixed economic data from China and the US.
Analysts at Jefferies noted that insider transactions at biotech firms are frequently tied to personal portfolio diversification rather than a bearish outlook on the company. “Rothblatt remains a significant shareholder, and this sale appears to be part of a routine 10b5-1 plan,” they said in a note. The broader healthcare sector on the FTSE 350 rose 0.2 per cent, with pharmaceutical stocks such as AstraZeneca and GSK providing modest support.
United Therapeutics has a market capitalisation of roughly $17 billion and continues to invest in its pipeline, including gene therapy and organ transplant technologies. The company is expected to report its second-quarter earnings in early August, which will be closely watched by investors on both sides of the Atlantic.